DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for congenital rubella — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCongenital rubella maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for congenital rubella is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
interleukin 6 (IL6) — IL6 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet +drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1ALU · 1.9 Å · ligand L(+)-TARTARIC ACID (TLA). Experimental structure, not a prediction.
What the evidence adds up to
A 2002 study followed 50 of Norman Gregg’s original congenital rubella patients, born 1939–1944, for 60 years. By 2000–2001, 10 had died: four from cardiovascular causes, four from malignant disease, one from AIDS, and one from hepatitis C-related cirrhosis. Among the 32 survivors who came for review (19 men, 13 women), echocardiography showed mild aortic valve sclerosis in 68%. The prevalence of diabetes was 22%, thyroid disorders 19%, early menopause 73%, and osteoporosis 12.5% — all increased compared with the Australian population. 41% had undetectable rubella antibodies. The haplotype HLA-A1, B8, DR3, associated with autoimmune conditions, was present in 25%.
A 1965 report on the US rubella epidemic described congenital rubella syndrome as including intrauterine growth retardation, thrombocytopenic purpura, cataracts or glaucoma, patent ductus arteriosus or septal defects, microcephaly, hydrocephalus or meningoencephalitis, hepatosplenomegaly, hepatitis, and bone lesions. Rubella virus was isolated from fetal tissues for weeks and months after maternal infection.
A 2012 case report from South Africa stated that congenital rubella syndrome has no cure but is almost completely preventable by immunisation. Two confirmed cases were diagnosed in a neonatal unit in 2011.
No drug treatment for congenital rubella syndrome is mentioned in any of these abstracts. The 2002 cohort study documents the lifelong burden of the condition but does not test any intervention. What is missing is any clinical trial of a drug for congenital rubella syndrome, any funding for such a trial, and any stratification of patients by the specific manifestations that might be targeted.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Medical Journal of Australia · 2002 · 90 citations
Gregg's congenital rubella patients 60 years later
AbstractBACKGROUND: In 1941, a Sydney ophthalmologist, Norman McAlister Gregg, correctly identified the link between congenital cataracts in infants and maternal rubella early in pregnancy. Fifty of Gregg's subjects with congenital rubella, born in 1939-1944, were reviewed in 1967 and again in 1991. We reviewed this cohort in 2000-2001, 60 years after their intrauterine infection. METHODS: The subjects underwent full clinical assessment, plus pathology tests, an ophthalmological and cardiological review (including electrocardiography and echocardiography) and HLA histocompatibility testing. RESULTS: Since they were first seen in 1967, 10 have died (cardiovascular causes [4], malignant disease [4], AIDS [1], and hepatitis C-related cirrhosis [1]). All surviving men came for review (19) and 13 women (eight women declined). Echocardiography showed mild aortic valve sclerosis in 68%. The prevalence of diabetes (22%), thyroid disorders (19%), early menopause (73%) and osteoporosis (12.5%) was increased compared with the Australian population; 41% had undetectable levels of rubella antibodies. The frequency of HLA-A1 (44%) and HLA-B8 (34%) antigens was increased, and the haplotype HLA-A1, B8, DR3, said to be highly associated with many autoimmune conditions, was present in 25%. CONCLUSIONS: This cohort of people with congenital rubella has illuminated our understanding of viral teratogenesis.
Australian and New Zealand Journal of Ophthalmology · 1994 · 27 citations · open access
A fifty‐year follow‐up of ocular defects in congenital rubella: late ocular manifestations
AbstractFifty patients born with congenital rubella in 1939-1945 were reviewed in 1967. In 1991 this cohort was again studied and their ophthalmic features are presented here. The presence of two new cataracts and one case of possible choroidal neovascularisation are again noted; apart from these three eyes, the group showed no evidence of other delayed manifestations of the congenital rubella syndrome. A review is given of the ocular complications of the congenital rubella syndrome, with particular emphasis on the late complications.
South African Journal of Child Health · 2012 · 10 citations · open access
Congenital rubella - is it nearly time to take action?
AbstractCongenital rubella syndrome (CRS) is a rare but potentially debilitating disease with lifelong consequences. Although there is no cure, it is almost completely preventable by an effective immunisation programme. We present two confirmed cases of CRS diagnosed in the neonatal unit at Groote Schuur Hospital in 2011 and discuss aspects of the disease and its prevention.
Abstracts1 November 1965Rubella and the Congenital Rubella Syndrome.Saul Krugman, M.D.Saul Krugman, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-63-5-914_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe epidemic of rubella in the United States in 1964 was followed by the birth of many thousands of infants with congenital rubella syndrome. This syndrome was characterized by one or more of the following manifestations: (1) intrauterine growth retardation, (2) thrombocytopenic purpura, (3) eye lesions (cataract or glaucoma), (4) congenital heart disease (patent ductus arteriosus or septal defects or both), (5) brain lesions (microcephaly, hydrocephalus or meningo-encephalitis), (6) hepatosplenomegaly, (7) hepatitis, and (8) bone lesions.Rubella virus isolatin studies by many investigators have revealed the following: (1) presence of virus in fetal tissues for weeks and months after maternal... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, New York PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 November 1965Volume 63, Issue 5Page: 914-915KeywordsGlaucomaHepatitisHepatosplenomegalyHydrocephalusInfantsIntrauterine growth restrictionLesionsMicrocephalyPatent ductus arteriosusRubella Issue Published: 1 November 1965 PDF downloadLoading ...
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
